Dataset Information

Quantitative proteomic analaysis of colorectal cancer

ABSTRACT: Colorectal cancer (CRC) remains among the topmost malignancy across the globe. It stands to be the leading cause of cancer mortality worldwide. It is the second most common cancer diagnosed in women and the third most in men that accounts for approximately 10% of cancers diagnosed annually. It will be worthwhile to identify and measure the dysregulated protein marker in order to comprehend illness pathobiology and improve disease diagnosis and therapy. This study utilizes high throughput quantitative tissue proteomics approach to study the dysregulation. This work aimed at examining proteomic dysregulation in human CRC tissue samples as compared to matched peritumoral tissue from a diverse patient population of Indian origin using Tandem Mass Tag (TMT) to identify potential biomarkers. The altered proteins from the study were further taken for biological pathway analysis to decipher the insights of disease biology. This study is one of the first comprehensive proteome-wide investigations of Indian CRC patients detecting potentially altered protein candidates in the disease development and metastasis which can be used as a potent biomarker.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Colon

SUBMITTER: Abhilash Barpanda

LAB HEAD: Dr. Sanjeeva Srivastava

PROVIDER: PXD039285 | Pride | 2025-10-13

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	19112021_Fusion_CAC_TMT_R1F-_1_.msf	Msf
	19112021_Fusion_CAC_TMT_R1F-_1_.pdResult	Other
	19112021_Fusion_CAC_TMT_R1F1.raw	Raw
	19112021_Fusion_CAC_TMT_R1F2.raw	Raw
	19112021_Fusion_CAC_TMT_R1F3.raw	Raw

Items per page:

1 - 5 of 25

Publications

Colon Adenocarcinoma Quantitative Proteomics Reveals Dysregulation in Key Cancer Signaling Pathways and a Candidate Protein Marker Panel.

Barpanda Abhilash A Halder Ankit A Dhote Ayushi A Parihari Shashwati S Kantharia Chetan C Srivastava Sanjeeva S

Omics : a journal of integrative biology 20230201 2

Colorectal cancer (CRC) is reportedly the second leading cause of cancer death worldwide. By the end of the decade, there will likely be more than one million fatalities worldwide from this cancer, with an estimated 2.2 million additional cases. We need new ways of thinking about cancer research. One approach is to deploy systems science using quantitative proteomics to obtain postgenomic and functional insights into cancer. The present study compares the tissue proteome of CRC (<i>n</i> = 10) w ...[more]

PMID: 36730729

Similar Datasets

Project description:Background: Platelets may be pivotal mediators of the thrombo-haemorrhagic complications of preeclampsia (PE), linking inflammation and thrombosis with endothelial and vascular dysfunction. While gestational hypertension (GH) falls within the spectrum of hypertensive complications of pregnancy and is a risk factor for preeclampsia, it is unclear what biomarkers distinguish PE from GH. Aim: To identify specific plasma and platelet thrombo-inflammatory biomarkers indicative of preeclampsia and distinguish PE from GH. Methods: We performed multiplex immunoassays, assessed platelet and plasma proteomics and metabolomics data of PE patients, and compared with non-pregnant (NP), healthy pregnant (PC) and GH participants. Results: We report plasma proteins upregulated, enriched plasma metabolites and proteins distinctly overexpressed in platelets of PE and GH compared to NP and PC. Whilst procoagulation in PC may be fibrinogen driven, Inter-Alpha-Trypsin Inhibitors ITIH2 and ITIH3 were enriched in hypertensive complications of pregnancy (PE and GH), and fibronectin and S100A8/9 may be major procoagulant agonists in PE but not GH. In addition, platelet leucine-rich repeat-containing protein 27 and 42 (LRRC27/42) subunits of volume-regulated VRAC anion channels were markedly overexpressed in preeclampsia and may contribute to the heightened glucose sensitivity and the pro-thrombotic tendency of this disorder. Additionally, our multiplex immunoassays confirmed previous reports of increases in preeclampsia plasma cytokines, including SDF-1α, which can directly activate platelets; but also, i-309 and CTACK cytokines, whose effects on platelets we explored using STRING analysis. Conclusion: We identified biomarkers that may be monitored for preeclampsia onset and progression, and distinguish PE from GH. Also, through protein-protein interactions analysis, we generated a new hypothesis for platelets’ contribution to the thrombo-inflammatory states of preeclampsia.